Journal
ISCIENCE
Volume 25, Issue 10, Pages -Publisher
CELL PRESS
DOI: 10.1016/j.isci.2022.105090
Keywords
-
Categories
Funding
- National Natural Science Foundation of China [31970165, 31701207]
- Wuhan Science and Technology Department [2019020701011503]
- Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province
Ask authors/readers for more resources
This study presents a novel approach using a recombinant reporter arenavirus to study the infection in real-time and screen for compounds that are active against arenaviruses both in vitro and in living mice.
Mammarenavirus are a large family of enveloped negative-strand RNA viruses that include several agents responsible for severe hemorrhagic fevers. Until now, no FDA-licensed drug has been admitted for treating an arenavirus infection, and only few effective anti-arenavirus drugs have been tested in vivo. In this work, we designed a recombinant reporter arenavirus lymphocytic choriomeningitis virus that stably expressed nanoluciferase (LCMV-Nluc). The LCMV-Nluc was proved to share similar biological properties with wild-type LCMV and the Nluc intensity reliably reflected viral replication both in vitro and in vivo. Replication of the Nluc-encoding virus in living mice can be visualized by real-time bioluminescent imaging, and bioluminescence can be detected in a variety of organs of infected mice. This work provides a novel approach that enables real-time study of the arenavirus infection and is a convenient and valuable tool for screening of compounds that are active against arenaviruses in vitro and in living mice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available